115 - Ditching the Dogma: Antimicrobial Stewardship Myth Busters

Friday, October 21, 2022

10:30 AM – 11:45 AM US ET

Location: 145 AB

Watch the live stream on the conference website.

All relevant financial disclosures have been mitigated.

Moderator(s)

Pranita Tamma, MD, MHS

Associate Professor
Johns Hopkins School of Medicine
Baltimore, Maryland, United States

Disclosure(s): No financial relationships to disclose
Erin McCreary, PharmD

Clinical Assistant Professor, Director of Infectious Diseases Improvement and Clinical Research Innovation
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania, United States

Disclosure(s): AbbVie Inc: Advisor/Consultant (Ongoing); Cidara Therapeutics Inc.: Advisor/Consultant (Ongoing); Entasis Pharmaceuticals: Advisor/Consultant (Ongoing); Ferring/Rebiotix Pharmaceuticals: Advisor/Consultant (Ongoing); La Jolla Pharmaceuticals: Advisor/Consultant (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Ongoing); Shionogi & Co.,Ltd.: Advisor/Consultant (Ongoing); Summit pharmaceuticals: Advisor/Consultant (Ongoing)

Faculty(s)

Navaneeth Narayanan, PharmD, MPH, BCIDP

Clinical Associate Professor
Rutgers University, Ernest Mario School of Pharmacy
New Brunswick, NJ, United States

Disclosure(s): Merck and Company, Inc.: Grant/Research Support (Ongoing)

Slides
Sarah Doernberg, MD, MAS

Associate Professor
University of California, San Francisco
San Francisco, California, United States

Disclosure(s): Basilea: Advisor/Consultant (); Genentech: Advisor/Consultant (); Gilead: Grant/Research Support (); Johnson and Johnson: Advisor/Consultant (); NIH: Grant/Research Support (); Regeneron: Grant/Research Support ()

Slides
Rebecca G. Same, MD

Assistant Professor
Children's Hospital of Philadelphia

Disclosure(s): No financial relationships to disclose

Slides

Disclosure(s):

Pranita Tamma, MD, MHS: No financial relationships to disclose

Erin K. McCreary, PharmD: AbbVie Inc: Advisor/Consultant (Ongoing); Cidara Therapeutics Inc.: Advisor/Consultant (Ongoing); Entasis Pharmaceuticals: Advisor/Consultant (Ongoing); Ferring/Rebiotix Pharmaceuticals: Advisor/Consultant (Ongoing); La Jolla Pharmaceuticals: Advisor/Consultant (Ongoing); Merck and Company, Inc.: Advisor/Consultant (Ongoing); Shionogi & Co.,Ltd.: Advisor/Consultant (Ongoing); Summit pharmaceuticals: Advisor/Consultant (Ongoing)

Navaneeth Narayanan, PharmD, MPH, BCIDP: Merck and Company, Inc.: Grant/Research Support (Ongoing)

Sarah B. Doernberg, MD, MAS: Basilea: Advisor/Consultant (); Genentech: Advisor/Consultant (); Gilead: Grant/Research Support (); Johnson and Johnson: Advisor/Consultant (); NIH: Grant/Research Support (); Regeneron: Grant/Research Support ()

Rebecca G. Same, MD: No financial relationships to disclose

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 contact hours of pharmacy CE
ACPE Number: JA0007082-0000-22-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

recognize the role of bacteriocidal antibiotic agents in the treatment of bloodstream infections;
identify the role of trimethoprim-sulfamethoxazole in the treatment of beta-hemolytic infections;
describe the role of doxycycline in children less than 8 years of age

Presentations:

10:30 AM – 10:55 AM US ET

Myth: Bactericidal Agents Are Necessary for the Treatment of Bloodstream Infections
Speaker: Navaneeth Narayanan, PharmD, MPH, BCIDP – Rutgers University, Ernest Mario School of Pharmacy
10:55 AM – 11:20 AM US ET

Myth: Trimethoprim-Sulfamethoxazole Is Not Effective for the Treatment of Skin and Soft Tissue Infections Involving Beta-Hemolytic Streptococci
Speaker: Sarah B. Doernberg, MD, MAS – University of California, San Francisco
11:20 AM – 11:45 AM US ET

Myth: Doxycycline Should Be Avoided in Children Less Than 8 Years Old
Speaker: Rebecca G. Same, MD – Children's Hospital of Philadelphia